| Literature DB >> 35643546 |
Ziqin Kang1, Tingting Jin2, Xueer Li3, Yuepeng Wang1, Tianshu Xu1, Yan Wang1, Zixian Huang4, Zhiquan Huang5.
Abstract
BACKGROUND: To assess the contributing risk factors for the progression of, and the postoperative poor prognosis associated with, osteoradionecrosis of jaw (ORNJ) following non-nasopharyngeal cancer treatment in head and neck.Entities:
Keywords: Chemotherapy; Flap reconstruction; Head and neck cancer; Meta-analysis; Non-nasopharyngeal cancer; Osteoradionecrosis of the jaw; Postoperative complication
Mesh:
Year: 2022 PMID: 35643546 PMCID: PMC9148447 DOI: 10.1186/s12903-022-02244-9
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 3.747
Demographic and clinical characteristics of study patients according to ORNJ
| Variable | |
|---|---|
| No. of patients | 124 |
| Mean (SD) range (years) | 57.6 (10.1), 32–83 |
| Sex (male/female) | 89/35 |
| Chemoradiotherapy/ Radiotherapy only | 46/78 |
| Type of primary tumor: | |
| Tongue carcinoma | 41 (33.1%) |
| Gingival carcinoma | 10 (8.1%) |
| Buccal carcinoma | 9 (7.3%) |
| Mouth floor carcinoma | 11 (8.9%) |
| Oropharyngeal carcinoma | 23 (18.5%) |
| Hard palate carcinoma | 3 (2.4%) |
| Salivary gland carcinoma | 6 (4.8%) |
| Carcinoma of jaw | 3 (2.4%) |
| Maxillary sinus carcinoma | 4 (3.2%) |
| Other | 14 (11.3%) |
| Mean (SD) range time from end of radiotherapy to development of osteonecrosis of the jaws | 4.5 (5.1) years, 1 months-32 years |
ORNJ osteoradionecrosis of jaw; SD standard deviation; No. number
Bone (B) and soft tissue (S) classification, and stage of osteonecrosis of the mandible
| Variable | Stage (n) |
|---|---|
| Bony destruction: | |
| BO (no bony exposure, only imaging) | 0 (6) |
| B1 (exposed bone, area < 2.0 cm) | B0S0 |
| B2 (exposed bone, ≥ 2 cm) | I (62) |
| B3 (pathological fracture) | B1S0,B1S1,B1S2 |
| Soft tissue injury: | II (44) |
| SO (no soft tissue damage) | B2S0,B2S1,B2S2 |
| S1 (mucosal or skin damage) | III (12) |
| S2 (mucosal and skin damage) | B3S0,B3S1,B3S2 |
Fig. 1The screening process was conducted according to the PRISMA flow-diagram. Ten articles were finally included in the meta-analysis
Characteristics of included patients: among 4906 patients who received surgery with jaw lesions, 475 ORN were diagnosed
| Study | No. of Patients | Mean time of follow-up (months) | Patients receiving surgery with jaw lesions | ORN patients with jaw lesions |
|---|---|---|---|---|
| Wang et al. [ | 25,246 | 19.1 | 2635 | 219 |
| Studer et al. [ | 531 | 38 | 36 | 16 |
| Sathasivam et al. [ | 325 | 44.1 | 84 | 33 |
| Renda et al. [ | 167 | 50.4 | 11 | 2 |
| Raguse et al. [ | 149 | 41 | 66 | 21 |
| Moon et al. [ | 252 | 25 | 21 | 2 |
| Liao et al. [ | 16,701 | 75 | 1122 | 77 |
| Kuhnt et al. [ | 776 | – | 90 | 26 |
| Kubota et al. [ | 616 | 40 | 51 | 7 |
| Chen et al. [ | 1692 | – | 790 | 72 |
ORN osteoradionecrosis; No. number
Fig. 2The forest plot graph shows the OD of risk of developing ORNJ in irradiated patients undergoing surgery with jaw lesions. Abbreviations: CI, Confidence Interval; I2, Higgins’ Hindex; IV, Inverse Variance
Evaluation of poor prognosis for different surgical approaches
| Postoperative complications | Treatment | Poor | Favorable | |
|---|---|---|---|---|
| Wound healing | Flap reconstruction (n = 40) | 6 (15%) | 34 (85%) | < 0.001b |
| Partial mandibulectomy (n = 17) | 8 (47%) | 9 (53%) | ||
| Curettage of non-vital bone (n = 33) | 19 (57.6%) | 14 (42.4%) | ||
| Disordered occlusion | Flap reconstruction (n = 40) | 8 (20%) | 32 (80%) | < 0.005b |
| Partial mandibulectomy (n = 17) | 11 (64.7%) | 6 (35.3%) | ||
| Curettage of non-vital bone (n = 33) | 13 (39.4%) | 20 (60.6%) | ||
| Nerve injury | Flap reconstruction (n = 40) | 12 (30.0%) | 28 (70.0%) | 0.152b |
| Partial mandibulectomy (n = 17) | 9 (52.9%) | 8 (47.1%) | ||
| Curettage of non-vital bone (n = 33) | 16 (48.4%) | 17 (51.6%) |
bPearson’s chi-square test
Effects of jaw lesions and chemotherapy for progression of ORNJ and the onset time compared with different variables
| Variables | All cases in study (n = 124) | Patients with BS stage 0, I | Patients with BS stage II, III | |
|---|---|---|---|---|
| Overall treatment | 0.018b | |||
| Radiotherapy only | 29 (23.4%) | 19 (65.5%) | 10 (34.5%) | |
| Radiotherapy and surgery with jaw lesions | 58 (46.8%) | 24 (41.4%) | 34 (58.6%) | |
| Radiotherapy and surgery without jaw lesions | 37 (29.8%) | 25 (67.6%) | 12 (32.4%) | |
| Surgery involving the jaw | 0.133b | |||
| Paramedian or median mandibular osteotomy | 20 (16.1%) | 5 (25%) | 15 (75.0%) | |
| Marginal mandibulectomy or maxillectomy | 30 (24.2%) | 14 (46.7%) | 16 (53.3%) | |
| Segmental mandibulectomy | 8 (6.5%) | 5 (62.5%) | 3 (37.5%) | |
| Surgery with flap reconstruction | 32 (25.8%) | 18 (56.2%) | 14 (43.8%) | 0.011b |
| Surgery without flap reconstruction | 26 (21.0%) | 6 (23.1%) | 20 (76.9%) | |
| Different jaw lesions with flap reconstruction | 0.115b | |||
| Paramedian or median mandibular osteotomy | 8 (6.4%) | 2 (25%) | 6 (75%) | |
| Marginal mandibulectomy or maxillectomy | 16 (12.9%) | 11 (68.8%) | 5 (31.2%) | |
| Segmental mandibulectomy | 8 (6.4%) | 5 (62.5%) | 3 (37.5) | |
| Paramedian or median mandibular osteotomy with flap reconstruction | 8 (6.4%) | 2 (25%) | 6 (75%) | 1.000b |
| Paramedian or median mandibular osteotomy without flap reconstruction | 12 (9.8%) | 3 (25%) | 9 (75%) | |
| Marginal mandibulectomy or maxillectomy with flap reconstruction | 16 (12.9%) | 11 (68.8%) | 5 (31.2%) | 0.014b |
| Marginal mandibulectomy or maxillectomy without flap reconstruction | 14 (11.3%) | 3 (21.4%) | 11 (78.6%) | |
| Chemoradiotherapy and jaw lesions | ||||
| Chemoradiotherapy | 46 (37.0%) | 17 (37.0%) | 29 (63.0%) | 0.004b |
| Radiotherapy only | 78 (63.0%) | 51 (65.4%) | 27 (34.6%) | |
| Chemoradiotherapy with jaw lesions | 16 (13.0%) | 1 (6.2%) | 15 (93.8%) | < 0.001b |
| Radiotherapy only with jaw lesions | 42 (33.9%) | 23 (54.8%) | 19 (45.2%) | |
| Chemoradiotherapy without jaw lesions | 30 (24.2%) | 16 (53.3%) | 14 (46.7%) | 0.036b |
| Radiotherapy only without jaw lesions | 36 (29.0%) | 28 (77.8%) | 8 (22.2%) | |
| Chemoradiotherapy with jaw lesions | 16 (13.0%) | 1 (6.2%) | 15 (93.8%) | 0.002b |
| Chemoradiotherapy without jaw lesions | 30 (24.2%) | 16 (53.3%) | 14 (46.7%) | |
| Radiotherapy only with jaw lesions | 42 (33.9%) | 23 (54.8%) | 19 (45.2%) | 0.033b |
| Radiotherapy only without jaw lesions | 36 (29.0%) | 28 (77.8%) | 8 (22.2%) | |
| Onset time of ORN, mean years ( | ||||
| Surgery with jaw lesions (n = 58) | 3.3 (3.8) | 0.008a | ||
| Surgery without jaw lesions (n = 66) | 5.7 (5.7) | |||
| Jaw lesions with flap reconstruction (n = 32) | 2.9 (3.3) | 0.484a | ||
| Jaw lesions without flap reconstruction (n = 26) | 3.6 (4.3) | |||
| Chemoradiotherapy (n = 46) | 4.3 (4.2) | 0.637a | ||
| Radiotherapy only (n = 78) | 4.8 (5.5) | |||
| Chemoradiotherapy with jaw lesions (n = 16) | 2.4 (3.6) | 0.331a | ||
| Radiotherapy only with jaw lesions (n = 42) | 3.5 (3.8) | |||
| Chemoradiotherapy without jaw lesions (n = 30) | 5.0 (4.3) | 0.396a | ||
| Radiotherapy only without jaw lesions (n = 36) | 6.3 (6.7) | |||
| Radiotherapy only with jaw lesions (n = 42) | 3.5 (3.8) | 0.025a | ||
| Radiotherapy only without jaw lesions (n = 36) | 6.3 (6.7) | |||
| Chemoradiotherapy with jaw lesions (n = 16) | 2.4 (3.6) | 0.041a | ||
| Chemoradiotherapy without jaw lesions (n = 30) | 5.0 (4.3) | |||
| Nasopharyngeal carcinoma patients (n = 180) | 6.8 (4.8) | < 0.001a | ||
| Non-nasopharyngeal carcinoma patients (n = 125) | 4.5 (5.1) |
aStudent’s t test
bPearson’s chi-square test